Last reviewed · How we verify
Pioglitazone Tablets
Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in type 2 diabetes.
Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Pioglitazone Tablets |
|---|---|
| Sponsor | Peking Union Medical College Hospital |
| Drug class | Thiazolidinedione (PPAR-γ agonist) |
| Target | PPAR-γ (Peroxisome proliferator-activated receptor gamma) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Diabetes |
| Phase | FDA-approved |
Mechanism of action
As a thiazolidinedione, pioglitazone binds to PPAR-γ in adipose tissue and muscle, enhancing insulin signaling and glucose uptake. This reduces hepatic glucose production and improves peripheral insulin sensitivity, leading to lower fasting and postprandial glucose levels. The drug also has favorable effects on lipid metabolism and may reduce cardiovascular risk in certain patient populations.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Weight gain
- Fluid retention / edema
- Hypoglycemia (when combined with other agents)
- Headache
- Upper respiratory tract infection
Key clinical trials
- The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD (PHASE4)
- A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy (PHASE4)
- Effect of Pioglitazone vs Metformin on Clinical, Biochemical and Hormonal Parameters of Insulin Resistant PCOS (NA)
- SGLT2i, Pioglitazone, and Ketone Production in T2D (PHASE1)
- A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (PHASE4)
- Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide. (NA)
- Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus (PHASE3)
- Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pioglitazone Tablets CI brief — competitive landscape report
- Pioglitazone Tablets updates RSS · CI watch RSS
- Peking Union Medical College Hospital portfolio CI